Clinical Trial Update: Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis [Phase 1]

View source ↗

Summary

Phase 1 study completed to evaluate the safety of GR-MD-02 in subjects with non-alcoholic steatohepatitis (NASH).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Steatohepatitis

Drugs mentioned

• GR-MD-02 (GR-MD-02)

Snippet

Sponsor: Galectin Therapeutics Inc. | Conditions: Non-Alcoholic Steatohepatitis (NASH) | Phase 1 | Status: COMPLETED